Skye Bioscience
SKYE
33 hedge funds and large institutions have $11.1M invested in Skye Bioscience in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 11 reducing their positions, and 2 closing their positions.
193% more call options, than puts
Call options by funds: $79K | Put options by funds: $27K
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
12% more capital invested
Capital invested by funds: $9.91M → $11.1M (+$1.19M)
6% more funds holding
Funds holding: 31 → 33 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.34% less ownership
Funds ownership: 6.04% → 5.7% (-0.34%)
82% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$33.9K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$28.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$22K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$21.2K |
| 5 |
GWM
Gilpin Wealth Management
Denver,
Colorado
|
+$6 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$46.9K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$46.5K |
| 3 |
BlackRock
New York
|
-$41.9K |
| 4 |
Two Sigma Investments
New York
|
-$15.8K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$15.7K |
SKYE Hedge Fund Activity: Q2 2026 in Review
33 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Skye Bioscience (SKYE) for Q2 2026, worth a combined $11.1M — up 12% from $9.91M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new SKYE positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 11 trimmed.
The largest buyer was Qube Research & Technologies (QRT), opening a new position worth an estimated $33.9K. The largest seller was Millennium Management, cutting an estimated $46.9K.
- 33 institutional investors held Skye Bioscience (SKYE) as of Q2 2026, up from 31 in Q1 2026.
- Funds reported $11.1M of Skye Bioscience stock for Q2 2026, up 12% quarter-over-quarter.
- 4 funds opened new Skye Bioscience positions in Q2 2026 and 2 closed out, a net change of +2 holders.
- The largest Skye Bioscience buyer in Q2 2026 was Qube Research & Technologies (QRT), an estimated $33.9K added.
- The largest Skye Bioscience seller in Q2 2026 was Millennium Management, an estimated $46.9K sold.
Based on aggregated 13F filings for Q2 2026.